Cardiol Therapeutics Inc.

TSX:CRDL.TO

Drug Manufacturers - Specialty & Generic

Healthcare
$1.36 +0.67%

+$0.00 today

Market cap
$164.10M
Beta
0.48
P/E (TTM)
-4.5
EPS (TTM)
-$0.33
52W Low $1.23High $2.33

Volume 0.08M

Average 0.12M

CRDL.TO Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Cardiol Therapeutics Inc.TSX: CRDL.TO

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue growth accelerates

Q1 FY2026 cost of revenue of CA$26.71K rose 6.9% year over year, ahead of the -23.4% change in trailing-twelve-month cost of revenue. Sequentially, it rose 2.8% from the prior quarter. Over 3 fiscal years it compounded at -22.6% a year.

Context

  • Cost of revenue increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +6.9% holds above the trailing-twelve-month pace of -23.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
CA$26.71K+2.8% QoQ
Last fiscal yearDec 2025
CA$101.98K-72.7% YoY
LTMMar 2026
CA$103.71K-23.4% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+6.9%——
1 year-72.7%——
3-year CAGR-22.6%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

CAD · from the income statement

Latest · FY2025
101.98K CAD
Year-over-year change
-72.7%
4-year CAGR
-17.5%

Cost of Revenue vs competitors

How CRDL.TO compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -23.4% is the lowest of 2, against a peer median of +122.0%.
  • Over three fiscal years its annual growth of -22.6% compares with a peer median of -1.1%.
CRDL.TO Competitors
Cost of Revenue for CRDL.TO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
HLS.TOHLS Therapeutics Inc.LTM Mar 2026$21.35M USD+122.0%+86.8%38.3%
CRDL.TOCardiol Therapeutics Inc.LTM Mar 2026CA$103.71K CAD-23.4%-22.6%—
MSCL.TOSatellos Bioscience Inc.LTM Mar 2026$5.77K USD—-88.9%—
Peer median (excluding CRDL.TO) —+122.0%-1.1%38.3%

Competitors are the stored peer set for CRDL.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CAD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue78.76K0000
Cost of Revenue220.42K219.91K248.36K373.11K101.98K
Gross Profit78.76K(219.91K)(248.36K)(373.11K)(101.98K)
Gross Margin100.0%————
Research & Development10.87M18.96M14.22M14.01M14.02M
Selling, General & Admin27.87M22.37M15.56M25.89M20.2M
Operating Expenses38.74M41.34M29.54M39.9M34.32M
Depreciation & Amortization220.42K219.91K248.36K373.11K101.98K
EBITDA(38.44M)(30.71M)(27.88M)(36.3M)(34.21M)
EBITDA Margin-48812.1%————
Operating Income(45.47M)(50.34M)(29.79M)(40.28M)(34.32M)
Operating Margin-57736.3%————
Interest Income106K1.24M2.04M1.19M726.4K
Interest Expense00000
Other Income / Expenses7.03M10.41M1.66M3.6M497.42K
Income Before Tax(31.64M)(30.93M)(28.13M)(36.68M)(33.82M)
Pre-Tax Margin-40170.4%————
Income Tax Expense(6.91M)(19.41M)000
Net Income(24.72M)(11.52M)(28.13M)(36.68M)(33.82M)
Net Margin-31391.5%————
EPS (Basic)(0.57)(0.18)(0.44)(0.51)(0.39)
EPS (Diluted)(0.57)(0.18)(0.44)(0.51)(0.39)
Weighted Avg Shares43.22M62.51M64.46M71.57M86.99M
Weighted Avg Shares (Diluted)43.22M62.51M64.46M71.57M86.99M

Cardiol Therapeutics Inc.

TSX:CRDL.TO

Intrinsic Alpha fair value

Locked

Current Price

$1.36

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.